- Home
- ZNB vs DRMA Comparison
ZNB vs DRMA Comparison
Compare ZNB & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNB | DRMA |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 2.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZNB | DRMA |
|---|---|---|
| Price | $0.74 | $2.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | N/A | ★ 95.9K |
| Earning Date | N/A | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $2.34 |
| 52 Week High | N/A | $23.70 |
Technical Indicators
Market Signals| Indicator | ZNB | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 36.63 | 41.90 |
| Support Level | $0.69 | $2.66 |
| Resistance Level | $0.79 | $2.98 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 27.41 | 53.66 |
Price Performance
Historical ComparisonAbout ZNB Zeta Network Group Class A Ordinary Shares
Zeta Network Group is an entertainment technology company with a network that focuses on the application of technology and artificial intelligence in the entertainment industry. It provides online entertainment performances and online education through its wholly-owned subsidiaries Color Metaverse and CACM. The curriculum developed by the company includes music, sports, animation, painting and calligraphy, film and television, and life skills, covering various aspects of entertainment, sports, and culture.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.